Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.62 |
| ▸ | STAT3 | P40763 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31361483 | 1.00 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326918 | 1.00 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326912 | 1.00 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL22291385 | 1.00 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326916 | 1.00 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL28576091 | 0.99 | CRBN (0.64) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326913 | 0.97 | CRBN (0.65) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL17873751 | 0.93 | CRBN (0.66) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL29546227 | 0.93 | CRBN (0.67) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884378 | 0.92 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11414416-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3676268-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | Dana-Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019079701-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885HDAC1 2077/4885 |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-11414416-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885HDAC1 2077/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | CRBN 7/4885DDB1 3044/4885HDAC1 467/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.